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The Role of Helicobacter pylori in Peptic Ulcer Disease 
Maria L. Partipilo, Pharm.D., and Patricia S. Woster, Pharm.D. 
The pathophysiology of peptic ulcer disease (PUD) is often described as an 
imbalance between aggressive factors such as acid and pepsin and alterations 
in the mucosal protective mechanisms. Helicobacter pylori is a gram-negative 
organism that has been identified as a potential causative agent in the 
pathogenesis of PUD. The exact mechanism by which it contributes to mucosal 
damage is unknown. It is thought that the organism may disrupt the protective 
mucous layer, allowing the underlying epithelium to be injured by gastric acid. 
Significant evidence indicates that H. pylori is a major etiologic factor in type B 
gastritis. Data confirming its etiologic role in duodenal ulcer (DU) disease is not 
conclusive; however, eradication of the organism is associated with a reduction 
in the recurrence of DU. Optimum therapy to eradicate H. pylori has not been 
established, although several multidrug regimens have been evaluated. 
Treatment of H. pylori infection should be reserved for individuals in whom 
conventional therapy for DU is unsuccessful and those whose ulcers relapse 
during maintenance therapy. 
(Pharmacotherapy 1993;13(4):330-339) 
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Conclusion 
The etiology of peptic ulcer disease (PUD) 
remains largely unknown despite extensive 
investigation. Most of the investigation and 
treatment over the past 30 years have focused on 
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the role of acid in the generation of ulceration. 
Treatment with agents that suppress acid 
secretion, such as histamine2-receptor antagonists 
(H2RAs), is a highly effective means of healing 
acute duodenal ulcers. Although these drugs can 
heal ulcers, they do not cure the disease. 
Recurrence rates among patients from whom 
treatment was withdrawn after 8 weeks are as high 
as 80% in the first year and reach 100% at 2 
years.’. Even in patients who continue therapy, 
cumulative recurrence is reportedly as high as 
48% after 1 year.3 Therefore, it appears that an 
imbalance between aggressive factors, such as 
acid and pepsin, and alterations in the mucosal 
protective mechanisms contribute to the 
pathophysiology of PUD. 
This theory suggests that the underlying 
pathophysiologic mechanisms of ulcerogenesis 
are unaltered with current treatment. Gastric acid 
is necessary for duodenal ulcers to form, but in 
most cases it appears that an alteration in the 
protective mechanisms of the duodenal mucosa 
must also play a role. This fact has prompted 
intense continuing investigation into the factors 
that might weaken the defenses of the gastric and 
duodenal epithelium. 
Helicobacter pylori is a gram-negative bacterium 
that has been identified as a potential causative 
agent in the pathogenesis of PUD.4 The organism 
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Table 1. Methods of Detecting H. pylori 
Method Advantages Disadvantages 
lnvasive 
Histology 
Warthin-Starry silver stain 
Giemsa stain 
Gram stain 
Culture of biopsy specimens 
Rapid urease test 
CLO test 
Noninvasive 
Urea breath test 
Nonradioactive CI3 
Radioactive CI4 
Serology 
ELISA 
Specificity and sensitivity 85-100%; 
direct visualization of gastrointestinal 
tract; gold standard with culture; 
inexpensive. 
susceptibility can be determined. 
Specificity approaches 100%; in vitro 
Rapid (75% positive within 20 min); 
represents entire mucosa; may replace 
culture if susceptibility not required. 
Specificity and sensitivity 90-1 00%. 
Rapid (60 min); represents entire mucosa. 
Ideal for mass screening. 
Two or more biopsies required. 
Sensitivity 50-90%; may require 1 wk 
for growth; recent use of antibiotic or 
H2RA may lead to false negatives; 
poor negative predictive value when 
used without histology. 
Expensive equipment required; 
radioactivity limits repeated tests, 
therefore reserved for follow-up. 
Presence of PUD not determined. 
Questionable reliability; possible 
cross-reactivity with similar bacteria. 
has been isolated from beneath the mucous layer 
and from the surface of gastric epithelium in a high 
percentage (70-1 00%) of patients with active 
chronic gastritis and duodenal ulcer (DU) disease.', 
4-6 Although its role in PUD is now well 
established, the mechanisms by which H. pylori 
predisposes patients to PUD remain controversial. 
The Organism 
In 1982 Warren and Marshall successfully 
cultured a spiral-shaped microorganism from the 
gastric antral mucosa of patients with gastritis or 
peptic ulcer.7 These organisms were originally 
designated as Campylobacter pyloridis due to their 
prepyloric location and their biochemical similarity 
with other campylobacteria. The species name 
was later changed to pylori ,  which was 
grammatically consistent with the nomenclature of 
other bacteria such as Campylobacter jejuni. After 
its successful culture, the taxonomic features of C. 
pylori underwent intense evaluation. A number of 
important morphologic and biochemical 
dissimilarities existed between it and true 
campylobacteria, including ultrastructure, cellular 
fatty acid composition, respiratory quinones, 
growth characteristics, RNA sequences, and 
enzymes.8-io Therefore, evidence existed that a 
new bacterial genus had been discovered, and 
thus in 1989 C. pylori was renamed Helicobacter 
pylori. li 
Helicobacter pylori has adapted to its environ- 
ment by developing four to six unipolar sheathed 
flagella that allow it to move freely in and beneath 
the mucous layer of the gastric It 
tends to cluster in the junctions between cells, 
rarely invading the cells. It is not viable in an acid 
environment; however, its location beneath the 
mucous layer and the release of urease, which 
produces a local alkaline environment capable of 
neutralizing gastric acid, allows its 6 ,  l 2  
Helicobacter pylori has been found only on gastric 
epithelial c e l l s . 2 ~ 5 ~  l3 Persons in whom it is 
colonized in the stomach may also harbor 
organisms in the metaplastic gastric epithelium of 
the esophagus (Barrett's esophagus) or 
duodenum.2 
Methods of Detection 
Helicobacter pylori may be detected invasively or 
noninvasively (Table 1). The gold standard is a 
combination of culture and histologic staining of 
biopsy specimens. Appropriate culture techniques 
can lead to the recovery of bacteria in 50-90% of 
infected Biopsies of both the antrum 
and the body of the stomach (due to the 
bacterium's nonuniform distribution) and prompt, 
careful handling of the culture are required to 
maximize the likelihood of detection. Warthin- 
Starry silver stain and Giemsa preparations are 
preferred for histologic detection.6 Histologic 
identification of H. pylori on the gastric epithelium 
surface correlates well with culture results, with a 
sensitivity and specificity range of 85-1 00%. 
The high urease activity exhibited by H. pylori 
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allows simple biochemical tests to detect the 
presence of the products of hydrolysis 
(ammonium) and, by inference, the presence of the 
organism. In the Carnpylobacter-like organism 
(CLO) test, a gastric biopsy specimen is placed in 
a solution that contains a small amount of urea, a 
pH indicator, and a bacteriostatic agent. If H. pylori 
is present, the urease produced will hydrolyze the 
urea, producing ammonia and a color change. 
This reaction is rapid, with broad sensitivity and 
specificity ranges of 65-95% and 60-1 OO%, 
respectively.2, 6,  1 4 ,  l 5  
The urea breath test, which also depends on 
bacterial urease activity, is a noninvasive way to 
detect H. pylori. A small dose of radiolabeled C13- 
or Ci4-urea is administered to subjects with a test 
meal to delay gastric emptying. Due to hydrolysis 
of a labeled carbon from the urea molecule by 
urease, radiolabeled carbon dioxide can be 
detected in the breath within 1 hour using a mass 
spectrometer to detect the stable Ci3 isotope, or a 
scintillation counter for the radioactive Ci4 isotope, 
if H. pylori is present in the stomach. This test has 
the advantage of being noninvasive, sensitive 
(90-1 0Oo/,), and specific (95-1 OOo/o). In addition, 
the results represent the entire mucosa rather than 
the small area provided by a random biopsy 
6, 14. l5 Disadvantages are that access 
to the necessary equipment may not be 
available, and repeat testing must be avoided 
due to the radioactivity. Further validation of this 
test is required before its routine use can be 
recommended. 
Antibodies directed against various H. pylori 
antigens can be detected in gastric juice and 
serum of infected persons, thus forming the basis 
of another noninvasive method of detection. 
Immunologic techniques using enzyme-linked 
immunosorbent assay (ELISA) demonstrate a 
strong correlation between high serum IgG and IgA 
antibody to H. pylori and gastric infection and 
inflammation. Use of whole-cell extracts of H. 
pylori as an antigen for ELSA should be avoided 
due to the cross-sensitivity with antibodies against 
other bacteria, resulting in loss of specificity. 
Further studies are necessary to determine if these 
tests are reliable indicators of the organism’s 
eradication .2, 6. 14, 
Epidemiology 
The association of H. pylori with PUD is well 
documented.2* 6, 1 3 .  l 5  Most infected people never 
develop ulcers, however, suggesting that the 
organism is not the only cause of PUD, but rather a 
requisite risk factor. The overall endoscopic 
isolation rate for H. pylori in patients complaining of 
dyspepsia ranges from 32-62% (mean 56%).15 
Studies performed in the Netherlands and the 
United States indicate the prevalence of H. pylori 
in healthy, asymptomatic subjects to be 
approximately 20%.16. The prevalence is age 
dependent: H. py/ori can be isolated in 10% of 
healthy individuals less than 30 years old and 
increases to 60% in those over age 60 years2, 5. 1 3 .  
The mode of transmission of H. pylori is still 
unknown, although person-to-person is most 
likely.5, 21. 22 Clustering within families and reports 
of higher than expected prevalence rates in 
nursing home residents support this ~ o n c e p t . ~  
Spread of the organism in endoscopy personnel 
also suggests this mode of transmission; the 
frequency in gastroenterologists is twice as high as 
22 The organism has been isolated 
from swine and nonhuman primates, but these 
sources cannot account for all i n f e c t i o n ~ . ~ ~  
Acquisition from food and environmental sources 
has not been dete~mined.~~ Clearly, infection from 
a common exogenous source cannot be 
completely ruled 
It is rare in asymptomatic ~hi1dren.I~ 
Mechanism of Injury 
Although the exact mechanism by which H. 
pylori contributes to mucosal damage is unknown, 
several mechanisms have been suggested. The 
inflammatory response associated with the 
organism may interfere with the production of 
gastric mucus and alter the hydrogen ion diffusion 
properties.2, 6, 15, 25 These changes may disrupt the 
protective mucous layer and allow injury to the 
underlying epithelium by gastric acid. In addition, 
local production of ammonia may damage cells 
through direct toxic effects or by raising pericellular 
pH, potentially leading to altered cellular 
permeability or active transport 1 3 -  l 5  
Alternatively, H. pylori may produce an unidentified 
toxin or chemotactic factor that promotes injury and 
inflammation. Finally, the pathogen adheres to the 
gastric metaplastic tissue in the duodenum; 
however, the role of attachment in the development 
of mucosal injury is not yet understood. 
Virtually all patients with duodenal ulcer, as well 
as many healthy individuals, experience gastric 
metaplasia in the duodenum .26 Helicobacter pylori 
may induce duodenitis in those areas, thereby 
disrupting the structure and function of the 
mucosa, and predisposing it to ulceration.2, l 5  
Furthermore, in the gastric antrum it may stimulate 
gastrin release, which increases gastric acid 
secretion and leads to ulceration. Gastrin release 
is decreased after eradication of the organism.27 
Prevalence in PUD 
Chronic Nonspecific Gastritis 
The prevalence of H. pylori in patients with 
chronic nonspecific gastritis (type B) ranges from 
70-1 00Y0.~ Type B gastritis primarily affects 
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Table 2. Evidence Refuting and Implicating a Pathogenic Role of H. pylori in Duodenal Ulcer Disease 
DU predominant in men; H. py/ori has no sex 
predilection. relapse rate. 
DU occurs in younger population; H. py/ori 
most prevalent in elderly. plus bismuth. 
Many individuals with H. pylorinever develop DU. 
Acid hypersecretion can cause DU without 
presence of H. pylori (Zollinger-Ellison). 
Ulcers heal in presence of bacteria. 
Refuting Evidence Implicating Evidence 
Persistence of H. py/oriafter ulcer healing leads to higher 
DU healing rate comparable with either H2RAs or antibiotics 
Recurrence of DU less likely after antimicrobial therapy vs H2RAs. 
Prevalence of H. py/ori in patients with DU approaches 100%. 
mucus-secreting antral-type gastric epithelium and 
the pyloris. It is characterized by chronic active 
inflammation, patchy gastric atrophy, and 
neutrophilic infiltration.28 
Several factors support a causal role of H. py/ori 
in this disease. Patients almost always show 
evidence of infection with the organism, and 
asymptomatic patients colonized with the organism 
always have histologic evidence of gastritis.’, An 
association exists between the number of 
organisms seen and the number of poly- 
morphonuclear leukocytes in the infected tissue.‘ 
In addition, eradication of H. pylori is associated 
with histologic impro~ement . ’~ .  29. 30 When two 
investigators with normal mucosa ingested live 
cultures of H. pylori ,  both developed acute 
g a s t r i t i ~ . ~ ’  The symptoms resolved with erad- 
ication of the organism. Even though it is agreed 
that H. pylori causes chronic nonspecific gastritis, it 
is unclear and perhaps unlikely that histologic 
gastritis causes dyspeptic symptoms or gross 
pathologic changes. 
Duodenal Disease 
The pathogen’s role in chronic duodenal disease 
is currently an area of great interest because the 
p reva I e n ce of H. pylori-assoc i a te d gastritis in 
patients with DU approaches 1 OOo/o.2. 6. 32, 33 
However, preliminary observations do not support 
the theory of a pathogenic role in duodenal disease 
(Table 2). Epidemiologically, DU predominantly 
occurs in men, and generally in young people (< 
30 yrs). In contrast, H. pylori is most prevalent in 
the elderly and has no sex predilection. In 
addition, patients with acid hypersecretion 
(Zollinger-Ellison syndrome) develop DU in the 
absence of H. pylori; in this patient population DU 
can be healed with therapy directed at acid 
suppression. Moreover, many individuals infected 
with the organism never develop DU.’. 
Conversely, overwhelming evidence to support 
H. pylori in the pathogenesis of DU can be found in 
antimicrobial treat men t trials .34-36 These trials 
suggest that persistence of H. pylori after ulcer 
healing leads to a significantly high relapse rate, 
l 7  
70-80% within 1 year. A comparable DU healing 
rate can be achieved with either H2RAs or 
antibiotics plus b i s r n ~ t h . ’ ~ ,  37 ,  38 However, 
recurrence of DU is less common after 
antimicrobial therapy than conventional therapy 
with the H2RA~.34, 36, 39 If H. pylori is eradicated, 
1 -year recurrence falls to 5-20%.40 
Gastric Ulcer 
In comparison with the prevalence of H. pylori in 
DU or chronic nonspecific gastritis, in gastric ulcer 
it is 60-80°/0.24 However, there is little difference in 
the prevalence in patients with gastric ulcer 
compared with that in age-matched controls 
without gastric ulcer.2, 15, 28 Because gastric ulcers 
are frequently associated with nonsteroidal 
antiinflammatory drug (NSAID) use, chronic active 
gastritis is typically not seen. If NSAID-associated 
gastric ulcers are excluded, however, the 
frequency of H. pylori and gastric lesions increases 
to 90%, a rate similar to that in duodenal disease.24 
The H. pylori-associated gastric ulcers are usually 
found along the transition zone between areas of 
inflammation and normal mucosa. 
Nonulcer Dyspepsia 
Nonulcer dyspepsia is a vague clinical syndrome 
that may comprise a variety of unexplained 
functional and inflammatory disorders of the upper 
gastrointestinal tract. Establishing a relationship 
between its symptoms, which include belching, 
nausea, and indigestion, and those of H. pylori 
infection is complicated by several factors. First, 
no universally accepted definition of nonulcer 
dyspepsia Furthermore, there is no 
difference in complaints of patients who have 
nonulcer dyspepsia with or without H. pylori. The 
frequency of H. pylori in patients with nonulcer 
dyspepsia is reported to be between 40% and 60% 
and is comparable to that in age-matched, 
asymptomatic controls. Some investigators 
demonstrated a higher percentage of H. pylori 
colonization in patients with symptoms of nonulcer 
dyspepsia, but the number of subjects was 
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Underlying Dose Duration of Time of Post-therapy Eradication 
(”/.) Therapy Assessment Disease Agent (mg/day) 
Bismuth alone 
Gastritis30 
DU, GU, NUD59 
NA48 
NA48 
NU D4‘ 
DU36 
Antibiotic alone 
Antral gastritis46 
Antral 
Bismuth plus antibiotic 
DU, GU, NUD5’ 
NAa 
DU36 
Triple therapy 
NA63 
DU. NUDM 
DW5 
DW7 
BSS 
BSS 
CBS 
CBS 
CBS 
CBS 
Amoxicillin 
Arnoxicillin 
Furazolidone 
Nitrofurantoin 
BSS 
Nitrofurantoin 
CBS 
Arnoxicillin 
CBS 
Tinidazole 
BSS 
Arnoxicillin 
Metronidazole 
CBS 
Tetracycline 
Metronidazole 
Tetracycline 
Metronidazole 
BSS 
Furazolidone 
Metronidazole 
Arnoxicillin 
3000 
2700 
960 
480 
480 
480 
2000 
2000 
400 
400 
2700 
400 
480 
750 
480 
1000 
1800 
1500 
1500 
480 
2000 
800 
2000 
750 
750 
600 
750 
1500 
3 wks 
28 days 
2 wks 
1-2 rno 
8 wks 
8 wks 
8 days 
14 days 
14 days 
14 days 
15 days 
10 days 
2 mo 
2 wks 
8 wks 
10 days 
2 wks 
2 wks 
2 wks 
4 wks 
4 wks 
10 days 
2 wks 
2 wks 
2 wks 
5 days 
5 days 
5 davs 
2 days 
Immediately 
3 mo 
Immediately 
3 mo 
Immediately 
3 mo 
2 days 
2 wks 
1 Yr 
2 days 
2 wks 
7 days 
1 mo 
1 day 
1.5 mo 
1 day 
1.5 mo 
Immediately 
2 wks 
Immediately 
3 mo 
2 wks 
1 Yr 
I mmediately 
4 wks 
4 wks 
19.3 mo 
Immediately 
3 mo 
6.5 mo 
78 
47 
18 
80 
0 
81 
27 
83 
32 
27 
91 
0 
72 
0 
86 
34 
58 
0 
60 
17 
100 
42 
74 
70 
100 
90 
94 
94 
37 
96 
54 
DU = duodenal ulcer; GU = gastric ulcer; NUD = nonulcer dyspepsia; BSS = bismuth subsalicylate; CBS = colloidal bismuth subcitrate; 
NA = not available. 
inadequate, and these trials failed to evaluate 
therapy in noninfected symptomatic 
Considerable variation exists in H. pylori 
eradication rates after treatment with colloidal 
bismuth subcitrate (CBS) in patients with nonulcer 
4144 Although CBS (DeNOL) 480 mg 
resulted in transient clearance of the organism and 
histologic improvement of the associated gastritis, 
literature reports disagree as to whether the agents 
i m prove symptoms. 41-44 Two studies that 
administered antibiotics (nitrofurans or amoxicillin) 
alone described no improvement of 46 
Studies are necessary to compare directly the 
frequency of H. pylori in patients with nonulcer 
dyspepsia with that in asymptomatic, age-related 
controls to determine a clinically convincing causal 
role in the disorder. 
Treatment of Helicobacter pylori Infection 
Eradication is the absence of H. pylori 1 month 
after discontinuation of therapy.6, 47 Early studies 
are misleading because relapse, rather than 
reinfection, was not appre~iated.~, 25 Follow-up of 
patients in whom the infection was thought to be 
eradicated showed that recurrent infections due to 
relapse are frequent and generally occur within a 
few weeks.35,48.49 Since the strain of organism that 
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emerges is usually identical to the original infecting 
strain, recurrent infections likely reflect relapse of 
the initial infection rather than r e i n f e c t i ~ n . ~ ~  The
optimum therapy to eradicate H. pylori is being 
evaluated (Table 3). 
Although the organism shows in vitro 
susceptibility to the p-lactams, macrolides, 
nitrofurans, and quinolones, in vivo eradication with 
a single-drug regimen is difficult.30, 35, 46. 50 Rapidly 
acquired resistance to antibiotics may be 
responsible for the lack of clinical efficacy. In 
addition, development of resistance may be due to 
the inoculum effect; that is, the significant increase 
in the minimum inhibitory concentration of an 
antibiotic when the number of organisms 
inoculated is increased. Since large numbers of 
the organism are present in the stomach, relative 
resistance due to the inoculum effect may occur. 
Furthermore, subpopulations of H. pylori that 
develop antimicrobial resistance may be 
Recrudescence of the infection after single-agent 
therapy with amoxicillin or bismuth without the 
development of resistance indicates that other 
factors may influence the effectiveness of 
50 
The development of resistance or relapse may 
be due to the patchy distribution of antibiotics over 
gastric mucosa, which results in a wide variation of 
drug concentration in the esophagus, stomach, 
and duodenum.50 Antimicrobial agents must reach 
the site of infection, attain sufficient concentration, 
and maintain activity in the local environment to be 
effective in vivo. The limited penetration of drug 
into the protected location of H. pylori, embedded 
in and covered by gastric mucus, and the 
decreased antibiotic activity due to local 
inactivation of the drug at a low pH may account 
for clinical f a i l ~ r e s . ~ ~ ~  50 Although H2RAs lack in 
vitro activity against H. pylori, they may serve as 
adjunctive agents by potentiating the gastric 
mucosal concentration of pH-sensitive  antibiotic^.^' 
Omeprazole 
Omeprazole decreases colonization rates of H. 
pylori when used as a single agent in the treatment 
of refractory DU and associated gastritis.52, 53 
Recent studies demonstrated that it causes 
temporary suppression rather than eradication of 
the organism.54, 55 Omeprazole causes a rise in 
gastric pH due to hydrogen ion pump inhibition. At 
this neutral pH, the ammonia produced by H. pylori 
is no longer neutralized by hydrogen ions and 
therefore may cause direct bacterial damage.54 In 
addition, omeprazole-induced achlorhydria may 
suppress H. pylori urease secretion, resulting in a 
biologically inactive bacteria. In its inactive state, it 
is postulated that the organism does not secrete 
phospholipases responsible for its path~genic i ty.~~ 
Because temporary suppression has been 
observed with omeprazole, i ts inclusion in 
regimens aimed at eradicating H. pylori is currently 
being evaluated. 
Bismuth 
Bismuth subsalicylate (Pepto-Bismol) and 
colloidal bismuth subcitrate (CBS; DeNOL) have 
been used in the treatment of gastrointestinal 
disorders for many years and are as effective as 
H2RAs in healing gastric and duodenal 40. 56 
Bismuth may contribute to healing by several 
cytoprotective mechanisms, including altering the 
mucous layer (making it more effective as a 
diffusion barrier to hydrogen ions), stimulating the 
synthesis of prostaglandins and reducing pepsin 
output, and modulating the immune r e s p o n ~ e . ~ ~ ~  33* 
5 1 3  56, 57 In addition, bismuth preparations exhibit 
bacte r i c i d a I action against H. pylori. 58 Mono- 
therapy with bismuth subcitrate lyses organisms in 
vivo within 30-90 minutes after admin is t ra t i~n.~~ 
Eradication ranging from 1 month to 1 year is poor, 
however, with rates of 0-27%.49, 59, 6o Successful 
regimens under investigation combine a bismuth 
preparation and one or two a n t i b i o t i c ~ . ~ ~ ~  59, 6o 
Coadministration seems to decrease antibiotic 
re~ is tance.~~ 
Bismuth subcitrate 120 mg 4 times/day is the 
most extensively studied, but the agent is not 
available in the United States.39$ 61, 62 Bismuth 
subsalicylate 525 mg (30 ml, or 2 tablets) is a safe 
and effective sub~t i tu t ion .~  Both preparations 
appear to be safe when used in the recommended 
dosages for up to 8 weeks.30, 393 42 Treatment for 
longer than 8 weeks with blood bismuth levels 
greater than 100 yglL has been associated with 
neurologic 5 6 3  6o Most cases were 
reported in the 1970s with large doses (up to 20 g 
elemental bismuth) of bismuth subnitrate, 
subgallate, or subcarbonate and are rarely 
reported with bismuth preparations available today. 
Treatment should be followed by an 8-week, 
bismuth-free interval, however, and patients with 
levels between 50 and 100 yg/L should be 
monitored for adverse reactions.39 The salicylate 
component also has the potential for toxic effects. 
Therefore, bismuth subsalicylate should be used 
with caution in children, individuals with salicylate 
sensitivity or bleeding disorders, those who are 
taking high-dose salicylates, and patients taking 
other drugs that may clinically interact with 
salicylate (e.g., anticoagulants, uricosuric agents, 
sulfonylureas, corticosteroids, meth~trexate).~~, 6o 
Combination Therapy 
Although the ideal treatment of H. pylori is 
unknown, bismuth salts seem to be an important 
component of therapy in patients with DU disease. 
Three prospective, randomized studies combining 
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a bismuth preparation and an antibiotic have been 
reported in sufficient detail to allow an adequate 
assessment of therapy.36 49. 59 The first long-term 
results were with a combination of bismuth and 
tinidazole, an investigational agent that is similar to 
metronidazole. In a double-blind study, 100 
patients with DU and H. pylori infection were 
randomly assigned to 8 weeks of cimetidine or 
CBS therapy with concurrent tinidazole or placebo 
during the first 10 days.36 Even when combined 
with tinidazole, cimetidine was ineffective against 
H. py/ori; the infection persisted in 95% of patients. 
The organism was eradicated in 27% of the CBS- 
placebo group and in 70% of the CBS-tinidazole 
group. In patients in whom H. pylori persisted after 
treatment, only 61 % had healed duodenal ulcers 
and 84% of these patients relapsed at 12 months. 
When H. pylori was cleared, 92% of ulcers were 
healed, and only 21% of patients relapsed during 
the 12-month follow-up period. This study 
suggests that eradication of the pathogen is a 
determining factor in ulcer relapse rates. However, 
ulcers did recur in some patients without persistent 
H. pylori infection. In other studies, therapy with 
drugs active against H. pylori (bismuth, 
metronidazole, amoxicillin) was associated with a 
significantly reduced rate of relapse compared with 
regimens without activity against the organism in 
patients with DU d i ~ e a s e . ~ ~ , ~ ~  
Results of studies using combination therapy 
with bismuth plus nitrofurantoin or amoxicillin are 
less impressive, with eradication rates of 17% 2 
weeks after the completion of a 14-day course of 
therapy and 42% 4 weeks after therapy, 
respe~t ively.~~~ 59 The duration of therapy in these 
studies was significantly shorter than that of the 
other study.36 
Failure of single- and two-drug regimens led to 
several multidrug regimens. Preliminary studies 
examining the treatment of H. py/ori with bismuth 
and two antibiotics show reasonably good 
eradication rates. A nonblinded, uncontrolled trial 
evaluated the efficacy of chewable bismuth 
salicylate tablets 600 mg, amoxicillin suspension 
500 mg, and rnetronidazole 500 mg 3 times/day for 
2 weeks in 23 patients with peptic ulcers.63 All 
patients were H. pylori negative at the end of 
therapy. Ten patients were reassessed 4 weeks 
after the cessation of therapy and 90% remained 
H. pylori negative by culture and biopsy. The time 
of follow-up in this study was short, and late 
relapses were not reported. Similarly, a 94% 
eradication rate was observed in 100 patients with 
nonulcer dyspepsia or DU 8 weeks after 
coadministration of chewable CBS tablets 120 mg, 
tetracycline 500 mg 4 times/day for 4 weeks, and 
metronidazole 200 mg 4 four times/day for 2 
weeks.64 Of the 64 patients available for 
reassessment in whom H. pylori remained 
eradicated at 8 weeks, 60 (94%) remained free of 
infection after a mean follow-up of 19.3 months.64 
Ranitidine 300 mg/day alone was compared with 
ranitidine plus tetracycline 500 mg 4 timeslday, 
metronidazole 250 mg 3 times/day, and bismuth 
subsalicylate 151 -mg tablets 5-8 times/day in 105 
Triple-antibiotic therapy was 
administered only during the first 2 weeks of the 
16-week trial. More rapid ulcer healing was 
reported with ranitidine plus triple-antibiotic therapy 
within 16 weeks. The respective cumulative 
percentages of patients with healed ulcers in this 
group and in the group receiving ranitidine alone 
were 37% and 18% after week 2, 84% and 68% 
after week 8, and 98% and 84% after week 16. A 
follow-up study evaluated the recurrence of gastric 
and duodenal ulcer after eradication of H. pylori in 
109 patients (83 with DU and 26 with gastric ulcer) 
for an average of 13 months.66 The investigators 
concluded that eradication leads to a significant 
reduction in the recurrence of symptomatic ulcers. 
The results of these studies provide further 
evidence that H. pylori infection plays a role in the 
pathogenesis of DU. 
In the first trial of 5-day, bismuth-free, triple-drug 
therapy for the eradication of H. pylori, 61 patients 
with DU received furazolidone 200 mg, 
metronidazole 250 mg, and amoxicillin 500 mg in 
combination 3 times a day for 5 days.67 Fifty-four 
percent of patients were negative for the organism 
6.5 months after the end of treatment, and 46% 
continued to be positive. Furthermore, 92% of the 
patients in whom the organism was eradicated 
showed endoscopically healed ulcers. The authors 
suggest that a shorter regimen may increase 
patient adherence to treatment, lower costs, and 
lessen the possibility of serious adverse effects 
with prolonged use of antibiotics. 
Although triple-drug therapy initially appears to 
be effective in eradicating the bacteria, the risks of 
antibiotic-associated diarrhea (Closfridium difficile 
disease) and antibiotic resistance must be weighed 
against the benefit. To date, no long-term studies 
on the efficacy of a long-term regimen to prevent 
relapse have been performed. Until an optimum 
regimen is established, only patients who have 
failed other treatment (H2RAs) should be 
considered to receive an antimicrobial plus 
bismuth. 
Investigational Agents 
An investigational product that combines 
ranitidine and bismuth citrate is currently 
undergoing phase Ill clinical trials in the United 
States. The new preparation, GR-l22311X, at a 
dosage of 391 mg twice/day was as effective as 
ranitidine 150 mg twice/day in decreasing 24-hour 
intragastric acidity in 30 healthy men 
This combination is aimed at enhancing the ulcer- 
healing benefit of an H2RA and may prove to be 
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very useful in the treatment of H. pylori. It remains 
to be determined whether it will enhance the 
healing as well as decrease the recurrence of 
PUD. 
Recommendations 
Since many patients with H. pylor i  are 
asymptomatic, the question becomes who would 
benefit from eradication of the bacteria. Strong 
evidence exists that H. pylori is the major cause of 
chronic nonspecific gastritis (type B). It is clear 
that eradicating the organism with amoxicillin, 
furazolidone, or bismuth salts leads to resolution of 
ga~tr i t is. ’~. 45. 46 However, asymptomatic patients 
with H. pylori-positive gastritis should not be 
treated because chronic nonspecific gastritis is not 
clearly associated with any specific symptoms or 
long-term sequelae. Furthermore, this subset of 
patients usually do not seek medical attention. 
The decision to eradicate H. pylori routinely 
when treating patients with nonulcer dyspepsia 
remains unclear. First, there is no convincing 
evidence that H. py/ori has a pathogenic role in 
nonulcer dyspepsia. Second, the gastric mucosa 
of patients complaining of similar dyspeptic 
symptoms is normal and the organism often is not 
detected. Finally, the optimum eradication therapy 
has not been established. Therefore, at the 
present time, specific treatment directed against H. 
pylori  i s  not recommended for patients with 
nonulcer 47, 50 
In general, investigators suggest that eradication 
therapy be reserved for patients in whom the 
benefits (reduced recurrence, cure) outweigh the 
risks (side effects of therapy, antibiotic resistance, 
etc.). Some suggest that patients with DU and 
gastric ulcer are most likely to benefit, and that this 
therapy is best aimed at preventing relapse.47 
Three well-controlled studies support the idea of 
treating patients with H. pylori 3 6 7  66 
Eradication in patients with healed DU resulted in a 
significantly lower relapse rate than those in 
patients not cleared of the organism.34’ 36 
Eradication may be associated with drug-related 
complications such as antibiotic-associated 
diarrhea. Failure to eradicate the organism may 
cause the development of antibiotic-resistant H. 
pylori, which could render the disease incurable 
using currently available antibiotics. Furthermore, 
eradication may not necessarily result in clinical 
cure because the patient may experience 
reinfection. While reinfection was uncommon in 
the present studies, the duration of follow-up was 
limited. Therefore, the best candidates in whom to 
attempt eradication of H. pylori are patients who 
have had no success with conventional treatment 
for DU and those whose ulcers recur. 
Currently, no agent is approved by the Food and 
Drug Administration for the treatment of H. pylori 
infection. Although most authors believe that 
therapy should be limited to controlled trials, 
several drug regimens have been proposed. One 
suggestion is bismuth subsalicylate 525 mg 4 
times/day plus metronidazole 250 mg 3 timeslday, 
administered over 4 weeks to patients in whom all 
other forms of therapy have failed but who remain 
s y m p t ~ m a t i c . ~  Gastric mucosal cultures and 
sensitivities should be obtained, and eradication of 
the organism confirmed 4-6 weeks after the 
cessation of therapy. A triple-drug regimen 
administers metronidazole 500 mg, chewable 
bismuth subsalicylate tablets 600 mg, and 
amoxicillin suspension 500 mg 4 times/day for 2 
weeks in patients with ulcers that fail to heal within 
12 weeks and whose symptoms are severe 
enough to make them candidates for surgery.24, 47 
A third recommendation is a combination of 
tinidazole 500 mg 2 times/day plus either bismuth 
subcitrate 120-mg tablets or amoxicillin 500 mg 
suspension 4 times/day for long-term eradication of 
H. pylori, provided the initial infecting strain is 
susceptible to n i t r o i m i d a z o l e ~ . ~ ~ ~  50, 69 Cultures 
should be obtained both before and after treatment 
to monitor the organism’s susceptibility to anti- 
microbial agents.50 A final suggestion is two 151 -mg 
bismuth subsalicylate tablets chewed 4 timeslday 
30 minutes before each meal for 2 weeks, plus 
tetracycline or amoxicillin 500 mg 4 times/day for 2 
weeks, plus metronidazole 250 mg 4 times/day for 
10 days.28 
Factors to enhance therapy have also been 
investigated. Administration of bismuth salts with 
meals will allow the drug to remain in the stomach 
as long as possible. The grinding and mixing 
functions of the stomach may also ensure 
maximum distribution within the stomach. In 
addition, since antacid tablets have a longer action 
than antacid liquids (possibly due to slower gastric 
emptying), bismuth tablets may be more effective 
than bismuth liquid.47 Finally, to ensure 
compliance, patients should be informed at the 
onset of therapy that two to three drugs will have to 
be taken several times a day for up to 4 weeks, 
and they must be willing to adhere to this regimen. 
Conclusion 
Significant evidence indicates that H. pylori is the 
major etiologic factor in type B gastritis. It is also 
associated with duodenal and gastric ulceration, 
and its eradication is associated with elimination of 
the recurrence of DU. Treatment should be 
considered on an individual basis. Patients should 
not be subjected to possibly ineffective or 
potentially toxic triple-drug regimens when safer 
treatment with H2RAs is available. The best 
candidates in whom to attempt eradication of H. 
pylori at the present time are individuals who have 
not had success with conventional treatment for 
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DU and those whose ulcers relapsed during 
maintenance therapy. 
The optimum therapy to eradicate H. pylori and 
the preferred duration of treatment remain to be 
established. Most investigators now agree that 
bismuth salts are an important component of 
eradication therapy. Evaluation of various other 
antimicrobial agents and H2RAs in combination 
with bismuth must be completed, as well as studies 
comparing dosage formulations, salts, and 
administration of bismuth in relationship to meals. 
Well-designed, controlled trials with prolonged 
follow-up to ensure long-term eradication of H. 
pylori are also needed. Questions remain 
concerning the best methods to detect the 
organism, and which one or combination of several 
is reliable and least expensive. Clinical trials to 
confirm that eradication leads to clinical 
improvement in symptomatic patients will have a 
major influence on the treatment of peptic ulcer 
disease in the future. 
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